InBody Co., Ltd.

As of March 31, 2026, InBody Co., Ltd. carries a market capitalization of 368.22B, placing it among publicly traded companies globally. Its enterprise value stands at 231.51B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

InBody Co., Ltd.'s next confirmed earnings release is scheduled for November 16, 2026.

As of March 31, 2026, InBody Co., Ltd. has 13.34M shares outstanding.

As of March 31, 2026, InBody Co., Ltd. trades at a trailing price-to-earnings ratio of 8.85. The price-to-sales ratio is 1.43, and the price-to-book ratio stands at 1.12.

As of March 31, 2026, InBody Co., Ltd. trades at an EV/EBITDA multiple of 4.47 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.94 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 5.41 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. InBody Co., Ltd. trades at an EV/FCF ratio of 7.45, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 231.51B versus a market cap of 368.22B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, InBody Co., Ltd. maintains a current ratio of 5.30, meaning it holds 5.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.57, indicating elevated leverage, while an interest coverage ratio of 101.36 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, InBody Co., Ltd. posted a return on equity (ROE) of 13.29, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 11.04 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 11.57, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 13.17, useful for judging operating efficiency across full business cycles. The company generates approximately 628.81M in revenue per employee across its workforce of 392.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.42 indicates how many times InBody Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, InBody Co., Ltd. recorded 9.09B in income tax expense. That works out to an effective tax rate of 18.72, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 48.53B, leaving 39.96B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, InBody Co., Ltd.'s stock has gained approximately 70.78% over the past 52 weeks. The 50-day moving average sits at 57,070.00, while the 200-day moving average is 43,089.50.

Over the twelve months ended March 31, 2026, InBody Co., Ltd. generated 246.81B in revenue and converted that into 39.96B in net income, yielding earnings per share of 3,076.73. EBITDA reached 51.78B, while operating income came in at 42.78B.

As of March 31, 2026, InBody Co., Ltd. holds 147.10B in cash and equivalents against 8.48B in total debt, resulting in a net debt position of -61.50B. Total book value stands at 328.65B, with working capital of 186.79B providing operational flexibility.

InBody Co., Ltd. produced 38.17B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -7.49B in capital expenditures, free cash flow totaled 30.67B - equivalent to 2,392.93 per share.

Over the twelve months ended March 31, 2026, InBody Co., Ltd. posted a gross margin of 77.07, reflecting its pricing power and cost economics. The operating margin of 17.33 and net profit margin of 16.19 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, InBody Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 8.67, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -4.14, meaning InBody Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

InBody Co., Ltd.'s most recent stock split took place on April 23, 2010 with a 1:2 split ratio.

As of March 31, 2026, InBody Co., Ltd. has an Altman Z-Score of 7.12, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.